In vitro study of the hemocompatibility of superparamagnetic contrast agent for magnetic resonance imaging

Saini, 1987, Ferrites particles: a superparamagnetic MR contrast agent for the reticuloendothelial system, Radiology, 162, 211, 10.1148/radiology.162.1.3786765 Pouliquen, 1989, Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: contribution of microencapsulation to improve biodistribution, Magn. Res. Imaging, 7, 619, 10.1016/0730-725X(89)90530-4 Weissleder, 1990, Superparamagnetic iron oxide: pharmacokinetics and toxicity, Am. J. Roentgenol., 152, 167, 10.2214/ajr.152.1.167 Fahlvik, 1990, Magnetic starch microspheres, efficacy and elimination: a new organ-specific contrast agent for magnetic resonance imaging, Invest. Radiol., 25, 113, 10.1097/00004424-199002000-00003 Pouliquen, 1990, Investigation of liver pathology with magnetite-dextran superparamagnetic nanoparticles as new MRI contrast agent, 234 Pouliquen, 1991, Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism, Magn. Res. Imaging, 9, 275, 10.1016/0730-725X(91)90412-F Chouly, 1992, Development of neutral superparamagnetic iron oxide nanoparticles (MD) as contrast agent for MRI of liver, spleen and MR lymphography, 865 Pouliquen, 1993, Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects, Magn. Res. Imaging, 11, 219, 10.1016/0730-725X(93)90026-A AFNOR (Association Française de Normalisation), NF S 90–702: 1988, Matériel médico-chirurgical—Evaluation in vitro de la cytotoxicité des matériaux et dispositifs médicaux. Parish, 1988, Automated colorimetric assay for T cell cytotoxicity, J. Immunol. Method., 58, 225, 10.1016/0022-1759(83)90277-6 Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Method., 65, 55, 10.1016/0022-1759(83)90303-4 Sgouras, 1990, Methods for the evaluation of biocompatibility of soluble synthetic polymers which have a potential for biomedical use: 1. Use of the tetrazolium based colorimetric assay (MTT) as a preliminary screen for evaluation of in vitro cytotoxicity, J. Mater. Sci.: Mater. Med., 1, 61, 10.1007/BF00839070 Lindley, 1965, Introduction to Probability and Statistics from a Bayesian Viewpoint, Part I: Probability, 135 Bordenave, 1992, New artificial connective matrix-like structures made of elastin solubilized peptides and collagens. II. Thrombogenicity and use as endothelial cell culture support, Biomaterials, 13, 439, 10.1016/0142-9612(92)90164-J ISO (International Organization for Standardization)/TR 7405: 1984, Biological evaluation of dental materials, Mayer, 1961, Complement and complement fixation, 133 Kojima, 1991, Interaction between phospholipids and biocompatible polymers containing a phosphorylcholine moiety, Biomaterials, 12, 121, 10.1016/0142-9612(91)90189-H Sawyer, 1991, In vitro hemocompatibility screening method for biomaterials, 669 Fahlvik, 1990, Magnetic starch microspheres: interactions of a microspheres MR contrast medium with macrophages in vitro, Int. J. Pharmaceut., 65, 249, 10.1016/0378-5173(90)90150-3 Miyamoto, 1989, Platelet aggregation induced by latex particles. I. Effects of size, surface potential and hydrophobicity of particles, Biomaterials, 10, 251, 10.1016/0142-9612(89)90101-4 Miyamoto, 1990, Mechanisms of blood coagulation induced by latex particles and the red blood cells, Biomaterials, 11, 385, 10.1016/0142-9612(90)90091-4 Mauzac, 1985, Anticomplementary activity of dextran derivatives, Biomaterials, 6, 61, 10.1016/0142-9612(85)90040-7 Crepon, 1987, Molecular weight dependency of the acquired anticomplementarity and anticoagulant activities of specifi cally substituted dextrans, Biomaterials, 8, 248, 10.1016/0142-9612(87)90111-6